NW
NWBO.US Northwest Biotherapeutics Inc
- Market cap
- USD 273M
- P/E
- -
- P/B
- 75.62x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NWBO.US undervalued?
Graham numberThe Graham number of Northwest Biotherapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Northwest Biotherapeutics Inc fundamental analysis
No fundamental analysis for Northwest Biotherapeutics Inc yet.
Northwest Biotherapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to…
Full company profileNorthwest Biotherapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Northwest Biotherapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 623K | 336K | 412K | 2.41M | 1.29M | 1.01M | 1.68M | 1.93M | 1.38M | 1.38M | 2.60M |
| Gross Profit | -79.3M | -54.7M | -44.8M | -27.5M | -86.6M | -52.7M | - | - | - | - | - |
| Operating Income | -79.3M | -54.7M | -41.5M | -27.5M | -86.6M | -52.7M | -67.2M | -55.5M | -66.5M | -59.9M | -45.0M |
| EBITDA | - | -67.2M | -24.6M | -17.3M | -521M | 185M | -97.5M | -55.6M | -74.0M | -49.7M | -12.9M |
| Net Income | -80.2M | -73.1M | -35.8M | -20.3M | -530M | 179M | -105M | -62.6M | -83.8M | -60.2M | -24.6M |
| EPS | -0.51 | -0.22 | -0.07 | -0.03 | -0.64 | 0.19 | -0.10 | -0.05 | -0.06 | -0.04 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 52.9M | 48.9M | 24.7M | 9.13M | 32.9M | 40.2M | 31.3M | 27.9M | 26.7M | 81.3M | 75.9M |
| Total Liabilities | 79.4M | 96.2M | 71.8M | 52.7M | 396M | 164M | 159M | 93.6M | 121M | 142M | 121M |
| Shareholders' Equity | -26.5M | -47.3M | -47.2M | -43.6M | -363M | -124M | -128M | -65.8M | -94.5M | -60.3M | -45.2M |
| Cash & Short-term Investments | 6.87M | 117K | 22.2M | 372K | 9.98M | 15.2M | 6.97M | 2.13M | 2.18M | 3.04M | 595K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -55.7M | -36.5M | -34.6M | -31.9M | -32.1M | -38.3M | -52.8M | -53.6M | -57.0M | -44.8M | -39.4M |
| Capital Expenditure | 4.94M | 8.00K | 193K | 360K | 6.61M | 6.02M | 2.90M | 3.44M | 1.01M | 1.50M | 654K |
| Free Cash Flow | - | -36.5M | -34.8M | -32.2M | -38.7M | -44.3M | -55.7M | -57.1M | -58.0M | -46.3M | -40.0M |
| Ratios | |||||||||||
| ROA | -151.6% | -149.6% | -145.1% | -222.3% | -1,610.4% | 446.0% | -335.3% | -224.7% | -313.4% | -74.0% | -32.4% |
| Net Profit Margin | -12,875.4% | -21,768.8% | -8,687.9% | -842.2% | -41,039.6% | 17,823.5% | -6,240.8% | -3,240.1% | -6,062.1% | -4,365.9% | -944.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Northwest Biotherapeutics Inc dividends
Northwest Biotherapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:16 on Sep 26, 2012.
Who owns Northwest Biotherapeutics Inc
- Insiders 4.11%
- Institutions 0.13%
- Public & others 95.76%
- Shares outstanding 1.71B
- Free float 1.74B
Northwest Biotherapeutics Inc company profile
- Company name
- Northwest Biotherapeutics Inc
- Ticker
- NWBO.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 105
- Fiscal year end
- December
- Address
- 4800 Montgomery Lane, Bethesda, MD, United States, 20814
- Phone
- 240 497 9024
- Website
- nwbio.com
About Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics Inc management
4- Ms. Linda F. Powers J.D.Chairperson, CEO, President, CFO & Chief Accounting Officer · born 1956
- Dr. Alton L. Boynton Ph.D.Founder, Chief Scientific Officer, Secretary & Director · born 1945
- Dr. Marnix L. Bosch M.B.A., Ph.D.Chief Technical Officer · born 1959
- Mr. David InnesVice President of Investor Relations